Ocugen Inc. (NASDAQ:OCGN) is one of the 10 best penny stocks that could triple your money. On March 24, Ocugen Inc.

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...

In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

A 16-year-old white girl was referred to the retina clinic by her pediatric ophthalmologist for evaluation of a worsening ...

Scientists at Royal Botanic Gardens Victoria, Australia have described two new species of fungi, Peziza austroechinospora and ...

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

German company Complement Therapeutics, which has a research laboratory at Stevenage Bioscience Catalyst, reports that the ...